13.17
Efeito da doença hepática na farmacocinética: avaliação fisiopatológica e teste de função hepática
Na prática clínica, a medição direta do fluxo sanguíneo hepático para avaliar a função do fígado apresenta desafios significativos devido à complexida…
Na prática clínica, medir diretamente o fluxo sanguíneo hepático para avaliar a função hepática é muitas vezes impraticável devido às técnicas especializadas necessárias.
Em vez disso, os médicos estimam a função hepática por meio do exame do paciente e dos testes de função hepática.
O Child-Pugh e o MELD ajudam a avaliar o comprometimento hepático, mas não se correlacionam diretamente com a farmacocinética do medicamento.
A doença hepática crônica afeta o metabolismo e a depuração do medicamento, exigindo uma avaliação de risco personalizada antes da dosagem.
A dosagem para pacientes com insuficiência hepática continua sendo uma área de desenvolvimento contínuo. No entanto, marcadores de medicamentos como aminotransferases, fosfatase alcalina, bilirrubina e tempo de protrombina fornecem informações valiosas sobre a função hepática.
Por exemplo, razões AST/ALT elevadas sugerem lesão hepática aguda, hepatite alcoólica ou fibrose hepática avançada, enquanto níveis elevados de PA podem indicar tumores hepáticos ou obstrução biliar.
Além disso, desvios nos níveis de bilirrubina urinária e no tempo de protrombina podem ajudar a diagnosticar doença hepatobiliar e insuficiência hepática, respectivamente.
View the full transcript and gain access to JoVE Core videos
Q1: Why can't clinicians directly measure hepatic blood flow to assess liver function?
Direct measurement of hepatic blood flow requires specialized techniques that are often impractical in clinical settings. Instead, clinicians estimate hepatic function through patient examination and liver function tests, which provide more accessible and reliable information for assessing drug metabolism and clearance in patients with liver disease.
Q2: What do the Child-Pugh and MELD scores tell us about drug pharmacokinetics?
While the Child-Pugh and MELD scoring systems effectively categorize hepatic impairment severity, they do not directly correlate with drug pharmacokinetics. These scores assess liver function but don't reliably predict how drugs will be metabolized or cleared in hepatically impaired patients, necessitating additional assessment for dosing decisions.
Q3: How do elevated AST and ALT ratios help diagnose liver disease?
Elevated AST/ALT ratios indicate acute liver injury, alcoholic hepatitis, or advanced liver fibrosis. These aminotransferase markers provide valuable insights into hepatic function and the liver's capacity to metabolize drugs, helping clinicians assess the degree of hepatic impairment and adjust medication dosing accordingly.
Q4: What does increased alkaline phosphatase suggest about liver health?
Increased alkaline phosphatase levels may indicate hepatic tumors or biliary obstruction, signaling potential compromise in liver function. This marker helps clinicians identify structural or metabolic abnormalities affecting the liver's ability to clear drugs and maintain functional capacity in patients requiring medication adjustments.
Q5: How do prothrombin time and urinary bilirubin levels differ in assessing hepatic disease?
Prothrombin time deviations signal hepatic failure or biliary obstruction by reflecting the liver's synthetic function, while variations in urinary bilirubin levels help diagnose hepatobiliary disease. Together, these markers provide complementary information about liver dysfunction and guide effect of hepatic disease on pharmacokinetics dose adjustments due to hepatic impairment.
Q6: Why does chronic liver disease require different dosing approaches than acute hepatitis?
Chronic liver disease significantly compromises drug metabolism and clearance, requiring systematic dosing adjustments. Acute hepatitis causes more nuanced metabolic changes, necessitating case-by-case assessment. Both conditions demand tailored risk evaluation before dosing, though establishing standardized guidelines for hepatically impaired patients remains an evolving area of clinical practice.
Q7: What role do liver function tests play in medication management for hepatic impairment?
Liver function tests measuring aminotransferases, alkaline phosphatase, bilirubin, and prothrombin time provide critical insights into hepatic function and drug clearance capacity. These markers enable clinicians to make informed decisions about tailored therapeutic interventions and medication adjustments, ensuring safe and effective treatment in patients with hepatic disease.